Why Liontown (ASX:LTR) could be a lithium share to buy in 2022

This could be a lithium share to buy…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Liontown Resources Limited (ASX: LTR) share price has been an exceptional performer over the last 12 months.

During this time, the lithium developer's shares have almost quadrupled in value.

A smiling woman holds an arm in the air in triumph while also holding a graphic of a fully-charged battery in her other hand.

Image source: Getty Images

Can the Liontown share price keep rising?

In light of the incredible rise in the Liontown share price since last year, some investors may be wondering if it's too late to invest.

The good news is that one leading broker doesn't believe it is. This week the team at Bell Potter retained its speculative buy rating and $2.15 price target on the company's shares.

Based on the current Liontown share price of $1.70, this implies potential upside of over 26% for investors.

What did the broker say?

Bell Potter notes that Liontown has just signed a binding spodumene offtake term sheet with leading battery manufacturer LG Energy Solution (LGES).

This five-year agreement is for 150ktpa spodumene with a target specification of 6% Li2O (SC6) at prices linked to industry recognised price reporting indices for lithium hydroxide monohydrate. This represents almost one-third of its initial planned production when it commences in 2024.

Its analysts commented: "LGES is a tier-1 counterparty being one of the premier global lithium ion battery manufacturers. The contract's linkage to lithium hydroxide price indices preserves LTR's value leverage to strong lithium markets and also enables LTR to capture some of the margin traditionally held by spodumene to lithium hydroxide chemical converters."

What else?

Outside this, the broker has previously spoken very positively about the company's future. Particularly given how its Kathleen Valley Lithium Project is fully-funded.

Bell Potter said: "LTR is funded for Kathleen Valley's initial development capital. A definitive feasibility study outlined 658ktpa SC6 production with potential for conversion into 86ktpa lithium hydroxide (75ktpa lithium carbonate equivalent, LCE). LTR is independent, debt free with significant uncommitted offtake; a strong strategic position in a market for lithium facing supply shortages. Key catalysts are awarding development contracts, procuring long lead-time equipment, signing offtake contracts and commencing development."

In respect to lithium supply shortages, earlier this week Liontown's CEO, Tony Ottaviano, refuted claims that high prices will lead to a supply surge. Particularly given how it takes between five to seven years to bring a mine from the exploration phase to production.

Mr Ottaviano was quoted in the Australian saying: "So all these people predicting tonnes from central Africa in 2023, there's a classic line in the movie The Castle ('tell 'em they're dreaming')."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »

Wlorker on a laptop on top of solar panels.
Broker Notes

Up 8%, should I buy the rebound in Origin Energy shares today?

A leading analyst provides his forecast for Origin Energy’s rebounding shares.

Read more »

A woman stands in a field and raises her arms to welcome a golden sunset.
Gold

4 ASX 200 gold shares to buy: Experts

Experts explain their buy ratings following these miners' June quarter reports.

Read more »

Three balls at various places on a cycle.
Broker Notes

6 ASX uranium shares to buy ahead of yellow cake rising to US$200 per pound: experts

This broker tips 83% to 295% upside over 12 months for its 6 top ASX uranium share picks.

Read more »